Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care

Kathleen Wiley RN, MSN, AOCNS®


As researchers learn more about how combination therapy combats drug resistance and lessens the changes of tumor evasion of the immune system, immune checkpoint inhibitors are receiving approval for a broader range of indications. However, recent U.S. Food and Drug Administration (FDA) approvals have centered around hematologic malignancies and the emergence of two new biosimilars.

View Article @

ONS Voice Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Voice Articles

Related Topics